{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T21:39:53Z","timestamp":1778362793308,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"vor","delay-in-days":1419,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.virol.2010.10.017","type":"journal-article","created":{"date-parts":[[2010,11,12]],"date-time":"2010-11-12T04:24:05Z","timestamp":1289535845000},"page":"348-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies"],"prefix":"10.1016","volume":"409","author":[{"given":"Ivonne","family":"Rubio","sequence":"first","affiliation":[]},{"given":"Hanna","family":"Seitz","sequence":"additional","affiliation":[]},{"given":"Elena","family":"Canali","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Sehr","sequence":"additional","affiliation":[]},{"given":"Angelo","family":"Bolchi","sequence":"additional","affiliation":[]},{"given":"Massimo","family":"Tommasino","sequence":"additional","affiliation":[]},{"given":"Simone","family":"Ottonello","sequence":"additional","affiliation":[]},{"given":"Martin","family":"M\u00fcller","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.virol.2010.10.017_bb0005","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1073\/pnas.0800868105","article-title":"Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2","volume":"105","author":"Alphs","year":"2008","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"9576","key":"10.1016\/j.virol.2010.10.017_bb0010","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"issue":"2 Suppl 1","key":"10.1016\/j.virol.2010.10.017_bb0015","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ygyno.2007.08.059","article-title":"Human papillomavirus vaccines and the potential for cross-protection between related HPV types","volume":"107","author":"Ault","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.virol.2010.10.017_bb0020","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1128\/JVI.79.11.6723-6731.2005","article-title":"Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection","volume":"79","author":"Bossis","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2010.10.017_bb0025","first-page":"445","article-title":"Generation of HPV pseudovirions using transfection and their use in neutralization assays","volume":"119","author":"Buck","year":"2005","journal-title":"Meth. Mol. Med."},{"issue":"2","key":"10.1016\/j.virol.2010.10.017_bb0030","doi-asserted-by":"crossref","first-page":"e4463","DOI":"10.1371\/journal.pone.0004463","article-title":"Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes","volume":"4","author":"Campos","year":"2009","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.virol.2010.10.017_bb0035","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/viro.1996.0554","article-title":"Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6","volume":"224","author":"Christensen","year":"1996","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.virol.2010.10.017_bb0040","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/viro.2001.1220","article-title":"Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types","volume":"291","author":"Christensen","year":"2001","journal-title":"Virology"},{"issue":"13","key":"10.1016\/j.virol.2010.10.017_bb0045","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1128\/JVI.76.13.6480-6486.2002","article-title":"Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses","volume":"76","author":"Combita","year":"2002","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.virol.2010.10.017_bb0050","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1128\/JVI.00143-08","article-title":"Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies","volume":"82","author":"Day","year":"2008","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.virol.2010.10.017_bb0055","doi-asserted-by":"crossref","first-page":"12565","DOI":"10.1128\/JVI.01631-08","article-title":"Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids","volume":"82","author":"Day","year":"2008","journal-title":"J. Virol."},{"issue":"21","key":"10.1016\/j.virol.2010.10.017_bb0060","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1128\/JVI.01577-07","article-title":"Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.virol.2010.10.017_bb0065","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"A protective and broadly cross-neutralizing epitope of human papillomavirus L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J. Virol."},{"issue":"19","key":"10.1016\/j.virol.2010.10.017_bb0070","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J. Med."},{"issue":"9518","key":"10.1016\/j.virol.2010.10.017_bb0075","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.virol.2010.10.017_bb0080","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines","volume":"101","author":"Jagu","year":"2009","journal-title":"J. Natl Cancer Inst."},{"issue":"7","key":"10.1016\/j.virol.2010.10.017_bb0085","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.73.7.6188-6190.1999","article-title":"Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6","volume":"73","author":"Kawana","year":"1999","journal-title":"J. Virol."},{"issue":"11\u201312","key":"10.1016\/j.virol.2010.10.017_bb0090","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0264-410X(00)00367-4","article-title":"Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies","volume":"19","author":"Kawana","year":"2001","journal-title":"Vaccine"},{"issue":"27\u201330","key":"10.1016\/j.virol.2010.10.017_bb0095","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1016\/S0264-410X(03)00454-7","article-title":"Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers","volume":"21","author":"Kawana","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.virol.2010.10.017_bb0100","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.virol.2006.08.037","article-title":"Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region","volume":"358","author":"Kondo","year":"2007","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.virol.2010.10.017_bb0105","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/jmv.21124","article-title":"Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes","volume":"80","author":"Kondo","year":"2008","journal-title":"J. Med. Virol."},{"issue":"14","key":"10.1016\/j.virol.2010.10.017_bb0110","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1128\/JVI.00571-07","article-title":"Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18","volume":"81","author":"Laniosz","year":"2007","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.virol.2010.10.017_bb0115","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J. Med."},{"issue":"9580","key":"10.1016\/j.virol.2010.10.017_bb0120","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"9686","key":"10.1016\/j.virol.2010.10.017_bb0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.virol.2010.10.017_bb0130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.virol.2005.04.011","article-title":"Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2","volume":"337","author":"Pastrana","year":"2005","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.virol.2010.10.017_bb0135","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1073\/pnas.0508815103","article-title":"Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection","volume":"103","author":"Richards","year":"2006","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"Pt 1","key":"10.1016\/j.virol.2010.10.017_bb0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1099\/vir.0.83145-0","article-title":"Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types","volume":"89","author":"Rizk","year":"2008","journal-title":"J. Gen. Virol."},{"issue":"13","key":"10.1016\/j.virol.2010.10.017_bb0145","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.vaccine.2009.01.102","article-title":"Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20\u201338) peptide displayed on bacterial thioredoxin","volume":"27","author":"Rubio","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2010.10.017_bb0150","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01088-09","article-title":"Chimeric L1\u2013L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines","author":"Schellenbacher","year":"2009","journal-title":"J. Virol."},{"issue":"1\u20132","key":"10.1016\/j.virol.2010.10.017_bb0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-1759(01)00376-3","article-title":"A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology","volume":"253","author":"Sehr","year":"2001","journal-title":"J. Immunol. Meth."},{"issue":"11","key":"10.1016\/j.virol.2010.10.017_bb0160","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.vaccine.2006.11.049","article-title":"A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11","volume":"25","author":"Slupetzky","year":"2007","journal-title":"Vaccine"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682210006641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682210006641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:11:20Z","timestamp":1758586280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682210006641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0042682210006641"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2010.10.017","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2010.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}